Clinical Research Unit in San Antonio, TX

{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services/clinical-pharmacology-unit-san-antonio-tx#webpage",
"url": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services/clinical-pharmacology-unit-san-antonio-tx",
"name": "Clinical Pharmacology Unit in San Antonio, TX",
"description": "Fortrea’s Clinical Pharmacology Unit in San Antonio, TX is a 200-bed, highly flexible, fit-for-purpose clinical pharmacology research unit supporting early phase clinical development, with more than 100 studies conducted annually in healthy volunteers, patients, and specialty populations, including CNS, cardiovascular, and metabolic patient populations. This clinical research unit in San Antonio offers a limited-access Phase I unit, adaptable procedure areas, telemetry units, an on-site cGMP Phase I compounding pharmacy for rapid investigational medicinal product preparation, CLIA-certified safety laboratory testing for screening and safety assessments, local pharmacokinetic bioanalytical validation, and Good Laboratory Practices testing for time-sensitive bioanalytical assay preparation following sample collection. The state-of-the-art facility includes a full-service clinical laboratory, a fully equipped sample processing laboratory that has delivered 600,000 samples in one year, security-alarmed -70°C and -20°C freezers, telemetry equipment, a centralized atomic clock system, and a pharmacokinetics laboratory with 14 centrifuges that handles more than 300,000 samples annually. Its 1,200-square-foot cGMP Phase I pharmacy includes a Class 10,000 clean room, an ISO Class 7 clean room, an ISO Class 5 laminar flow hood, Federal and state Schedule I-V drug licensure, and analytical balances with capabilities as low as 2 mg, and operates under GCP, USP 797, and FDA cGMP Guidance for Phase I investigational drugs. The San Antonio clinical pharmacology unit services cover first-in-human single ascending dose and multiple ascending dose studies, drug-drug interaction studies, QT cardiac safety studies, food-effect studies, pharmacokinetic and pharmacodynamic studies, bioequivalence and bioavailability studies, AME radiolabeling studies, and research involving renal- or hepatic-impaired patient populations. Specialized clinical pharmacology procedures include serial and continuous cerebrospinal fluid collection, CNS cognitive evaluation, inhalation and intranasal delivery, intratympanic injection, drug-alcohol interaction studies, female oral contraceptive-drug interaction studies, and respiratory dose administration. The unit also supports impaired renal or hepatic function, healthy elderly, metabolic syndrome, adolescent, low-testosterone, post-menopausal, and NASH populations. Its full-service early phase program support includes protocol design, early phase concept and program development, protocol writing, regulatory and pre-IND/IND meeting consultation services, scientific consultation, multi-site feasibility support through an established QA-approved site network, dedicated Phase I and early development project management, Phase I-focused data management, biostatistics and statistical design planning, pharmacokinetics, clinical monitoring, pharmacovigilance, site management, and medical writing, making Fortrea’s CRU in San Antonio a comprehensive clinical pharmacology unit for Phase I clinical conduct and early development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Clinical Solutions",
"item": "https://www.fortrea.com/clinical-solutions"
},
{
"@type": "ListItem",
"position": 3,
"name": "Clinical Pharmacology Services",
"item": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services"
},
{
"@type": "ListItem",
"position": 4,
"name": "Clinical Pharmacology Unit in San Antonio, TX",
"item": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services/clinical-pharmacology-unit-san-antonio-tx"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization (CRO) providing Phase I-IV clinical development, clinical pharmacology, patient access, and post-approval research services to biopharmaceutical, biotechnology, and medical device companies worldwide. Backed by more than 30 years of clinical research experience and one of the industry's earliest CRO legacies, from Covance through its evolution within Labcorp to today's independent Fortrea, the company combines scientific expertise, operational excellence, and Fortrea Intelligent Technology to deliver data-driven clinical trial solutions. Fortrea's network includes dedicated Clinical Research Units (CRUs) in Madison, Daytona Beach, Dallas, Austin, San Antonio and Leeds supporting first-in-human studies, clinical pharmacology, bioavailability and bioequivalence research, and early clinical development programs. Through a patient-centric approach and technology-enabled innovation, Fortrea helps sponsors accelerate development timelines, improve trial quality, strengthen patient outcomes, and advance life-changing therapies from early development through commercialization.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": ["https://www.linkedin.com/company/fortrea", "https://www.threads.net/@fortreacro","https://twitter.com/fortrea", "https://www.youtube.com/@Fortrea/", "https://www.facebook.com/Fortrea-104143099267108","https://www.instagram.com/fortreacro"
]
},
{
"@type": "NewsArticle",
"@id": "https://ir.fortrea.com/news-releases/news-release-details/fortrea-completes-acquisition-early-phase-services-division#newsarticle",
"url": "https://ir.fortrea.com/news-releases/news-release-details/fortrea-completes-acquisition-early-phase-services-division",
"publisher":{
"@type":"Organization",
"name":"Fortrea",
"logo":"https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"headline": "Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials",
"mainEntityOfPage": "https://ir.fortrea.com/news-releases/news-release-details/fortrea-completes-acquisition-early-phase-services-division",
"articleBody": "Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials\n\nAdds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas\n\nExpands Fortrea’s early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities\n\nEnables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions\n\nStrengthens Fortrea’s end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation\n\nSupports Fortrea’s growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company’s ability to create long-term value for shareholders\n\nProvides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies\n\nDURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials. The division consists of a Clinical Research Unit (“CRU”) and Bioanalytical Laboratory operations, in an all-cash transaction valued at approximately $45 million.\n\nThe acquisition strengthens Fortrea’s end-to-end clinical development platform by adding a 200-bed Good Clinical Practice-compliant CRU in San Antonio, Texas; a 60,000-square-foot Good Laboratory Practice-compliant bioanalytical laboratory in Austin, Texas; and a biospecimen storage facility in Pflugerville, Texas. Together, these assets expand Fortrea’s early-phase capacity to more than 570 beds globally and add in-house large and small molecule bioanalytical capabilities to support clients from first-in-human studies through proof-of-concept and later-stage development.\n\n“Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform,” said Anshul Thakral, CEO of Fortrea. “This transaction demonstrates tangible progress in Fortrea’s return to growth as we invest in our ability to win new opportunities and create lasting value for clients. By bringing together complementary clinical pharmacology and bioanalytical capabilities, we expect to expand the speed, flexibility and talent we can offer clients as they advance increasingly complex development programs. We are pleased to welcome the Early Phase Services team to Fortrea and look forward to delivering a seamless experience for clients, volunteers and the patients we ultimately serve.”\n\n“With this investment, Fortrea adds capability and capacity in its commitment to help clients design and execute early development programs with greater speed, scientific rigor and operational connectivity,” said Scott Dove, Ph.D., president, Clinical Pharmacology Services at Fortrea. “The addition of dedicated bioanalytical capabilities and expanded CRU capacity gives our teams more ways to support both simple and complex studies, streamline execution and generate high-quality data that inform development decisions.”\n\nThe addition of these capabilities complements Fortrea’s existing Clinical Pharmacology Services business and broadens its North American CRU footprint. The combined platform is designed to reduce operational handoffs between clinical and bioanalytical functions, improve turnaround times and provide clients with greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea’s early development network.\n\nFortrea and Worldwide Clinical Trials have also entered into agreements intended to support continuity for clients, employees and ongoing programs. Both organizations remain focused on maintaining project momentum and providing a seamless transition for employees, clients and volunteers.\n\nThe acquired Early Phase Services operations are now part of Fortrea’s Clinical Pharmacology Services business unit.\n\nAdvisors\n\nBarclays served as financial advisor to Fortrea, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as its legal counsel.\n\nAbout Fortrea\n\nFortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.\n\nCautionary Statement Regarding Forward-Looking Statements\n\nThis press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: the parties’ ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the anticipated benefits of the acquisition may not be realized, or may be realized more slowly or to a lesser extent than expected, difficulties, delays, costs or disruptions associated with integrating the acquired business, operations, employees, systems and processes into the Company, the ability to retain existing customers and business relationships of the acquired operations and win new business following the acquisition, the ability to retain and integrate key employees of the acquired business, the parties’ ability to perform their respective obligations under transition services and other agreements, unanticipated liabilities, expenses or adverse effects associated with the acquired business, the ability to maintain applicable regulatory, quality and accreditation requirements for the acquired sites, and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company’s business, see the “Risk Factors” Section of the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (the \"SEC\"), as such factors may be amended or updated from time to time in the Company’s subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company’s filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments.\n\nFortrea Contacts\n\nGalen Wilson (Media) – 703-298-0802, media@fortrea.com\nKate Dillon (Media) – 646-818",
"datePublished": "2026-10-19"
},
{
"@type": "MedicalBusiness",
"@id": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services/clinical-pharmacology-unit-san-antonio-tx#facility",
"name": "Clinical Pharmacology Unit in San Antonio, TX",
"description": "Fortrea's Clinical Pharmacology Unit San Antonio, TX is a full-service, fit-for-purpose clinical pharmacology research unit established in 2005 and designed to support sponsors across every stage of early clinical development. This 20,000-square-foot state-of-the-art facility conducts more than 100 studies annually across healthy volunteers, patients, and specialty populations and has been recognized by sponsors for quality and service. The facility features flexible procedure areas, a dedicated Phase I unit, a fully operational cGMP Phase 1 pharmacy with a Class 100,000 clean room, ISO Class 5 laminar flow hood, Federal and State Schedule I-V drug licensure, and FDA cGMP-compliant investigational drug capabilities. Its integrated CLIA-certified safety laboratory provides rapid turnaround testing, local pharmacokinetic bioanalytical validation, blood laboratory processing, telemetry equipment, centralized atomic clock systems, and secure -70°C and -20°C storage. Supporting complex studies, the facility processes more than 600,000 samples annually, while pharmacy operations utilize 14 centrifuges and manage more than 300,000 samples per year. Fortrea's extensive clinical pharmacology study experience includes First-in-Human studies, single and multiple ascending dose studies, drug-drug interaction studies, QT cardiac safety evaluations, food effect studies, PK/PD assessments, bioavailability and bioequivalence studies, AME studies, and renal and hepatic impairment research. Clients choose Fortrea for specialized clinical pharmacology procedures including serial and continuous CSF collection, inhalation and intranasal delivery, intralymphatic injection, female drug-drug interaction studies, and respiratory dose administration. The unit supports a broad range of patient and special populations, including renal impairment, hepatic impairment, metabolic disorders, adolescent populations, low testosterone, pre-menopausal populations, and NASH. Sponsors benefit from a dedicated medical point of contact, immediate access to senior leadership, scientific consultation, protocol development, regulatory and pre-IND guidance, feasibility assessments, project management, biostatistics, pharmacokinetics, clinical monitoring, pharmacovigilance, medical writing, and site management, making Fortrea's clinical research unit San Antonio a comprehensive destination for integrated clinical pharmacology unit services and early phase development excellence.",
"url": "https://www.fortrea.com/clinical-solutions/clinical-pharmacology-services/clinical-pharmacology-unit-san-antonio-tx",
"branchOf": {
"@id": "https://www.fortrea.com/#organization"
},
"address": {
"@type": "PostalAddress",
"streetAddress": "2455 Northeast Loop 410 Suite 150",
"addressLocality": "San Antonio",
"postalCode": "78217",
"addressCountry": "USA"
},
"parentOrganization": {
"@id": "https://www.fortrea.com/#organization"
}
},
{
"@type": "Service",
"name": "Clinical Pharmacology Services",
"provider": {
"@type": "Organization",
"name": "Fortrea"
},
"hasOfferCatalog": {
"@type": "OfferCatalog",
"name": "Clinical Pharmacology Unit in San Antonio, TX",
"itemListElement": [
{
"@type": "Service",
"name": "Protocol design and early phase concept and program development"
},
{
"@type": "Service",
"name": "Protocol writing"
},
{
"@type": "Service",
"name": "Regulatory and pre-IND/IND meeting consultation services"
},
{
"@type": "Service",
"name": "Scientific consultation"
},
{
"@type": "Service",
"name": "Multi-site feasibility support based upon established QA-approved site network"
},
{
"@type": "Service",
"name": "Dedicated Phase I/early development project management group"
},
{
"@type": "Service",
"name": "Phase 1 focused data management"
},
{
"@type": "Service",
"name": "Pharmacokinetics"
},
{
"@type": "Service",
"name": "Clinical monitoring"
},
{
"@type": "Service",
"name": "Pharmacovigilance"
},
{
"@type": "Service",
"name": "Site management"
},
{
"@type": "Service",
"name": "Biostatistics and statistical design planning specific to early development studies"
},
{
"@type": "Service",
"name": "Medical writing"
}
]
}
}
]
}